Jonathan M. Peacock

Chief Financial Officer, Amgen.

Companies

AvantorBoard member May 16, 2019 to now¹
Bellerophon Therapeutics (United States)Board member Feb 13, 2015 to Apr 2, 2021²
Kite PharmaBoard member Jun 19, 2014 to Oct 5, 2017³
Bellerophon Therapeutics (United States)Chief executive officer Feb 13, 2015 to May 18, 2016²
Bellerophon Therapeutics (United States)President Feb 13, 2015 to May 18, 2016²
AmgenChief financial officer Sep 2, 2010 to Oct 29, 2013⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Avantor AVTR219,815 shares⁵$3.6M at $16.31May 8, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

May 8, 2025Granted 17,100 shares of Avantor⁵
Apr 28, 2025Bought 8,091 shares at $12.81 of Avantor⁶
May 9, 2024Granted 8,477 shares of Avantor⁷
May 11, 2023Granted 9,808 shares of Avantor⁸
May 12, 2022Granted 6,693 shares of Avantor⁹
Apr 1, 2022Granted 1,215 shares of Avantor¹⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAvantor, Board member
2
SEC EDGARBellerophon Therapeutics (United States), Board member
3
SEC EDGARKite Pharma, Board member
4
SEC EDGARAmgen, Chief financial officer
5
SEC EDGARAvantor shares after the filing of May 8, 2025
6
SEC EDGARForm 4 filed Apr 29, 2025
7
SEC EDGARForm 4 filed May 13, 2024
8
SEC EDGARForm 4 filed May 15, 2023
9
SEC EDGARForm 4 filed May 16, 2022
10
SEC EDGARForm 4 filed Apr 5, 2022